Hi gingerclam,Along the same lines of your thinking… on the Acadia results call in the Q&A, when Serge was asked about the potential for trofinetide to address other indications, (time: 52:30) you’d think given the successful results, there might be at least a hint of optimism here. Instead, he fluffed around, mentioned TBI, ultimately agreed yes but finished with … it’s a little premature to go there and we’re focused on Retts getting it to FDA approval. Maybe he’s just a straight shooter but no mention of Fragile X had me wondering his agenda. Keeping Neuren affordable?
-
- There are more pages in this discussion • 795 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
$12.85 |
Change
-0.110(0.85%) |
Mkt cap ! $1.598B | |||
| Open | High | Low | Value | Volume |
| $12.82 | $13.05 | $12.53 | $6.559M | 511.8K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 1657 | $12.83 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $12.85 | 6303 | 1 |
View Market Depth
| Last trade - 16.10pm 17/06/2025 (20 minute delay) ? |
| NEU (ASX) Chart |